Cilazapril

證據等級: L5

預測適應症: 4 個

Cilazapril: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism

One-Sentence Summary

Cilazapril is an ACE (angiotensin-converting enzyme) inhibitor belonging to the RAAS drug class, classically used for the treatment of hypertension and heart failure. The TxGNN model predicts it may be effective for Pulmonary Hypertension with Unclear Multifactorial Mechanism (Group 5 PH), with no clinical trials and no direct publications currently supporting this specific indication.

Quick Overview

Item	Content
Original Indication	Hypertension / Heart Failure (ACE inhibitor class; no Saudi Arabia registration on file)
Predicted New Indication	Pulmonary Hypertension with Unclear Multifactorial Mechanism
TxGNN Prediction Score	99.20%
Evidence Level	L5
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Cilazapril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II (Ang II), thereby reducing systemic vasoconstriction, lowering blood pressure, and decreasing aldosterone secretion. It belongs to the same drug class as Ramipril and Lisinopril, which have well-documented cardiovascular and renal protective effects.

The mechanistic connection to pulmonary hypertension with unclear multifactorial mechanism (Group 5 PH) runs through the RAAS pathway: Ang II promotes pulmonary vasoconstriction and vascular remodeling, so ACE inhibition could theoretically reduce pulmonary vascular resistance. This pathway-level similarity is likely what drove the high TxGNN score, as the model operates on biological network topology rather than direct clinical endpoints.

However, this theoretical plausibility does not translate to clinical practice. ACE inhibitors are not included in any current guideline as treatment for pulmonary arterial hypertension or Group 5 PH. The TxGNN score almost certainly reflects RAAS graph-topology similarity rather than a genuine therapeutic signal. There are currently no clinical trials or disease-specific publications to support this prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Saudi Arabia Market Information

Cilazapril has no registered authorizations in Saudi Arabia (SFDA). There are no approved products, licensed indications, or dosage forms on record. Any future use would require a new regulatory filing.

Safety Considerations

Please refer to the package insert for safety information.

Note — Critical Safety Signal for Rank 4 Prediction: Although the primary focus of this report is the top-ranked indication, the evidence pack flags a clinically important contraindication for the rank 4 prediction (malignant renovascular hypertension): in patients with bilateral renal artery stenosis or stenosis of a solitary kidney, GFR maintenance depends on Ang II–mediated efferent arteriolar tone. ACE inhibition removes this compensatory mechanism and can precipitate acute kidney injury. This is a known absolute contraindication for ACE inhibitors in renovascular hypertension and must be factored into any clinical evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high score (99.20%) based on RAAS pathway graph similarity, but there is zero clinical trial evidence, zero disease-specific literature, and no regulatory precedent supporting Cilazapril for pulmonary hypertension with unclear multifactorial mechanism. An L5 evidence level is insufficient to justify advancement toward clinical evaluation without foundational data.

Summary of All Four Predicted Indications:

Rank	Indication	Evidence Level	Recommendation
1	Pulmonary hypertension with unclear multifactorial mechanism	L5	Hold
2	Pulmonary hypertension owing to lung disease and/or hypoxia	L5	Hold — 20 PubMed hits retrieved are general hypoxia biology papers, not Cilazapril-specific (likely keyword co-occurrence false positives)
3	Malignant hypertensive renal disease	L4	Research Question — mechanistically plausible via ACE inhibitor class effect (AASK trial precedent for Ramipril/Lisinopril), but no Cilazapril-specific data
4	Malignant renovascular hypertension	L5	Hold — known contraindication: bilateral renal artery stenosis risk of AKI with ACE inhibition

To proceed, the following is needed:

Retrieve full MOA documentation from DrugBank to formally confirm mechanistic plausibility
Conduct a systematic review of ACE inhibitor class-level evidence across PH subtypes (Group 1–5) before concluding on Cilazapril
Obtain and parse the package insert (SFDA or equivalent) for complete warnings, contraindications, and DDI profile — currently a blocking data gap
Assess whether Rank 3 (malignant hypertensive renal disease) warrants a separate, more focused evidence-gathering effort, given that the ACE inhibitor class has RCT-level support (AASK trial) for hypertensive nephropathy
Determine the regulatory pathway for first-time SFDA registration of Cilazapril in Saudi Arabia before any repurposing strategy can be operationalized
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.